Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia
July 30, 2020 07:00 ET
|
Imara, Inc.
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Added to Membership of U.S. Small-Cap Russell 2000® Index
June 29, 2020 16:01 ET
|
Imara, Inc.
BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Gazelle® Diagnostic Platform, Designed for Low Resource Settings, Integrates Miniaturized Technologies with AI to Transform Disease Screening and Diagnosis
June 17, 2020 03:01 ET
|
Hemex Health
8-minute, Low-Cost Diagnostic Test for Sickle Cell Disease (SCD) Among First Approved Tests Includes a One-Minute Malaria Test with Solutions for Other Health Priorities to Follow PORTLAND, Ore. and...
Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress
June 12, 2020 07:00 ET
|
Imara, Inc.
Showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks of...
Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress
May 21, 2020 07:00 ET
|
Imara, Inc.
BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Reports First Quarter 2020 Financial Results and Business Highlights
May 07, 2020 07:00 ET
|
Imara, Inc.
Strengthened Board of Directors and expanded leadership team with appointment of General Counsel Continued progress toward initiation of Phase 2b clinical trials of IMR-687 in sickle cell disease and...
Imara Launches ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders
May 06, 2020 07:00 ET
|
Imara, Inc.
BOSTON, May 06, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces Appointment of Stephen M. Migausky as General Counsel
May 04, 2020 07:00 ET
|
Imara, Inc.
BOSTON, May 04, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.
April 23, 2020 07:00 ET
|
Imara, Inc.
Industry leader with global clinical development expertise to help guide Imara’s clinical advancement Imara also announces departure of Chief Medical Officer, Willem Scheele BOSTON, April 23, 2020 ...
PAI Life Science’s Biochemistry Expertise Links with Hemex Health’s Gazelle™ Miniaturized Rapid Diagnostic Platform to Develop Pandemic Test
April 15, 2020 11:00 ET
|
Hemex Health
SEATTLE and PORTLAND, Ore., April 15, 2020 (GLOBE NEWSWIRE) -- Researchers in Seattle and Portland have agreed to collaborate on an urgently needed rapid COVID-19 diagnostic test that can diagnose...